Is Semaglutide Bad for You? Separating Myth from Clinical Reality

The biggest myth: 'semaglutide is dangerous' (and why it persists)

Most of the alarming headlines about semaglutide trace back to a handful of things: early reports of thyroid tumours in rodents, high-profile celebrity misuse of the diabetes formulation Ozempic for cosmetic weight loss, and a wave of counterfeit pens that caused hospitalisations not because of semaglutide itself but because of what the fakes contained. None of those stories, taken fairly, tells you that semaglutide is bad for people who genuinely need it and take it through a proper clinical route.

The rodent thyroid findings have not translated to the same effect in human studies to date, though the SmPC lists a history of medullary thyroid carcinoma or MEN2 as a reason not to use it. The Wegovy weight-loss licence is for adults, on a supervised schedule, alongside diet and lifestyle change, not an injectable shortcut for people who do not have a clinical need. That context matters enormously when you are reading about risk.

The STEP 1 trial, which underpinned Wegovy's UK approval and was published in the New England Journal of Medicine, ran for 68 weeks and recorded side effects systematically across nearly 1,300 participants. Serious adverse events occurred at similar rates in the semaglutide and placebo groups. That is a meaningful data point, and it is the one often absent from the alarm-driven coverage.

The side effects that are genuinely common, and what usually happens to them

The honest answer is that most people taking semaglutide will experience some gastrointestinal disruption, particularly early on. Nausea is the most reported effect. Loose stools, constipation, indigestion, reflux and burping follow in frequency. The pattern is familiar to prescribers: symptoms are worst in the first few weeks or after moving up the titration schedule, then often settle as the body adjusts.

The slow dose escalation built into the licensed pathway exists specifically to reduce these effects. Starting low and titrating gradually is not a formality, it is what makes the medicine tolerable for the majority of people. If you want a detailed breakdown of the less pleasant end of the side-effect profile, bloating and gas on Wegovy is covered separately because it is one of the questions our prescribers hear most often.

Fatigue and headache are also reported, particularly in the early weeks. Injection-site reactions (redness, itching at the abdomen, thigh or upper arm) are generally mild. The NHS semaglutide medicines page lists these in full and distinguishes between effects to monitor and effects that require urgent attention.

The side effects that are rarer but genuinely serious

This is the section people actually need. Three risks deserve clear explanation rather than either dismissal or alarm.

Acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines specifically because of this. Pancreatitis is infrequent but can be severe. The warning sign to act on is persistent, severe stomach pain that spreads toward your back, sometimes accompanied by vomiting, sometimes not. If that happens, stop taking the medicine and seek urgent medical help. Do not wait for your next scheduled review. The broader adverse effects profile of semaglutide covers this in more depth.

Gallbladder problems. Rapid weight loss of any kind increases gallstone risk, and semaglutide is no exception. Symptoms include upper-right abdominal pain, particularly after fatty food. This is worth knowing ahead of treatment, not as a reason to avoid it, but so you recognise what to report.

Dehydration and kidney strain from severe GI illness. If nausea and vomiting are severe enough that you cannot keep fluids down, this can lead to dehydration quickly. Staying hydrated and contacting a clinician early if GI symptoms are persistent matters more than pushing through.

Allergic reactions are rare but possible. Sudden changes in vision should also prompt medical review, particularly in anyone with a history of diabetic eye disease. If any of these occur, reporting via the MHRA Yellow Card scheme supports ongoing medicine safety monitoring for everyone who takes these medicines.

Who semaglutide is and is not suitable for

The licensed UK criteria for Wegovy are adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Meeting those numbers is the starting point, not the whole picture, a prescriber also looks at your medical history, current medicines, and any contraindications.

It is not suitable during pregnancy, while breastfeeding, or if you are trying to conceive in the near term. It is not licensed for anyone under 18. A personal or family history of medullary thyroid carcinoma or MEN2 syndromes, or a history of pancreatitis, requires careful prescriber discussion before starting.

Oral contraceptive pill absorption may be less affected by semaglutide than by tirzepatide, though it is worth discussing with a prescriber regardless. If you have questions about how a GLP-1 medicine fits alongside other treatments, the deeper look at Wegovy's risk profile addresses common combinations. For a broader overview of what is available and what the evidence shows, including information for those specifically looking into Wegovy in Glasgow, our weight-loss treatment overview is a useful starting point before a consultation.

If semaglutide sounds like something worth exploring, a free clinical consultation with a GPhC-registered prescriber at nume will give you an honest answer based on your specific circumstances. Start your free consultation here.